PMGC Holdings unit reports Phase III drug discovery results with Yuva

NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), announced results from Phase III of an AI-driven drug discovery program conducted with Yuva Biosciences, Inc.

The phase used Yuva Biosciences' MitoNova™ AI platform to select small-molecule candidates, which were then tested in primary human skeletal muscle cells using an in vitro assay measuring ANT1 protein expression. ANT1 is a mitochondrial protein involved in cellular energy metabolism in skeletal muscle.

Four compounds — identified as C1, C2, C3, and C4 — each demonstrated statistically significant increases in ANT1 expression. The strongest observed increases were C2 at up to 50%, C4 at up to 48%, and C1 at up to 46%. C3 showed a 29% increase at the highest tested dose. C1, C2, and C4 were identified as the most dose-consistent inducers.

Yuva Biosciences recommended advancing all four candidates into a more mature skeletal muscle model to further confirm ANT1 induction. NorthStrive Biosciences and Yuva Biosciences stated they are evaluating next steps, including confirmatory testing.

The results are based on in vitro testing and are described as preliminary. The companies noted there is no assurance that any candidate will show similar activity in future testing, animal studies, or clinical studies.

According to the press release, the drug discovery program is focused on muscle preservation, with potential applications related to muscle health and metabolic stress.

You May Also Be Interested In

• Oracle wins $6.99B DoW software contract under ESI program
• Oriental Culture shifts from e-commerce to third-party platform services
• Norfolk Southern (NSC) PT Raised to $358 at Evercore ISI